Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.
February is kicking off with a number of PDUFA dates for the U.S. FDA as well as a cancer advisory committee meeting. Here’s a look.
It was a busy week for clinical trial news. Read on for more information.
Today marked some wheeling and dealing in the life sciences industry as several companies licensed products or invested in other companies. Here’s a look.
A team led by Dr. Decio Eizirik, M.D., Ph.D., Scientific Director for Indiana Biosciences Research Institute Diabetes Center, has taken a step back from the traditional immune system study approach and found potential for treatment and, theoretically, even a cure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
The U.S. Food and Drug Administration approved Merck and Bayer’s heart failure drug vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, the pharma giants announced this morning.
JOBS
IN THE PRESS